Metoprolol is utilized exclusively or combined with other suppositories to get rid of hypertension. Decreasing high blood pressure assists in avoiding strokes, seizures, and kidney complications. This medication is correspondingly used to get rid of upper body pain and to recover subsistence after a stroke (Larosa & Kostis, 2013). Metoprolol is acknowledged as one of the beta-blocker medications. It works by obstructing the effect of several natural substances on MT’s body. This includes the level of epinephrine and the blood vessels. This outcome normalizes the heart rate and heart tension. This medicine may similarly be used for heart failure, unbalanced heartbeat, headache deterrence (migraines), shocks, and other circumstances.
We will write a custom Essay on Hypertension and Dyslipidemia: Prevention and Treatment specifically for you
301 certified writers online
MT should utilize this medication repeatedly to get the most of it (Larosa & Kostis, 2013). She should take it daily (it is also crucial to take it at the same time every day). Nonetheless, MT should not abruptly quit taking this medicine as her state may become poorer when the treatment is unexpectedly stopped. Dealing with high blood pressure may take an extensive period before MT gets the full advantage of this medication. It is central to remain taking this medicine even if she feels fine (Larosa & Kostis, 2013). To avert upper body discomfort, a subsequent stroke, or migraines, it is central to take this suppository recurrently as given.
The dynamic component ezetimibe, which is a kind of medication identified as a lipid absorption obstructer. Ezetimibe attempts to avoid cholesterol and supplementary vegetal sterols being engrossed into MT’s blood flow from the minor intestine. It correspondingly stops cholesterol that is unconstrained from the bile canal into the bowel from being repeatedly captivated back into the blood circulation (Jellinger et al., 2012). The general outcome is a decrease in cholesterol levels in the plasma. Hypertension is spotted among individuals who take Ezetimibe, particularly for women that are older than 50, have been taking the medication for at least two years, also take suppository similar to Aspirin, and suffer from hypertension.
The nurse recommends a wide-ranging approach to regulating sterol levels and address accompanying metabolic irregularities and adjustable risk aspects such as hypertension, diabetes, overweight, and smoking (Burst & Benzing, 2011). The initial approach to principal deterrence in patients with overweight ailments includes the employment of régime deviations, together with corporal actions and therapeutic nourishment treatment (Larosa & Kostis, 2013). The treatment may as well comprise patient instruction agendas to endorse additional risk lessening through quitting smoking and losing weight. The medication the nurse recommends to take instead of ezetimibe is pravastatin (Larosa & Kostis, 2013).
It lets down “adverse” lipid and increases “upright” cholesterol in the individuals who cannot do this through nourishment régime and physical activities. It can also diminish the risk of a seizure, heart attack, and demise, predominantly if MT has high blood pressure/ diabetes or smokes cigars (Jellinger et al., 2012). Since the utmost outcome of a prescribed dose is realized during a month, intermittent lipid evaluations should be done throughout this time and dosage attuned by the results. The preliminary pravastatin dose is 40 mg one-time-a-day (orally) and the preservation dose ranges from 40 to 80 mg a day (Jellinger et al., 2012).
MT should change her lifestyle to decrease the risk aspects that she can regulate. This includes quitting smoking, watching her weight, upholding a healthy body mass, and working out often. MT should eat healthy food with low cholesterol levels. She could also receive detailed references or directed to a dietician for healthy diet development.
Burst, V., & Benzing, T. (2011). Dyslipidemia Treatment and Cardiovascular Disease in the Renal Patient. Current Pharmaceutical Design, 17(9), 894-907. Web.
Jellinger, P., Smith, D., Mehta, A., Ganda, O., Handelsman, Y., Rodbard, H.,… Seibel, J. (2012). American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocrine Practice, 18(Supplement 1), 1-78. Web.
Larosa, J. C., & Kostis, J. B. (2013). Dyslipidemia in Hypertension. Hypertension: A Companion to Braunwald’s Heart Disease, 320-326. Web.